Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP349706.RAf3w2LwF3gvMjBdzhuqZS9tQjel9GGPsNYQ1bmuR1zMw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP349706.RAf3w2LwF3gvMjBdzhuqZS9tQjel9GGPsNYQ1bmuR1zMw130_assertion type Assertion NP349706.RAf3w2LwF3gvMjBdzhuqZS9tQjel9GGPsNYQ1bmuR1zMw130_head.
- NP349706.RAf3w2LwF3gvMjBdzhuqZS9tQjel9GGPsNYQ1bmuR1zMw130_assertion description "[With the advent of targeted signal transduction therapy, patients with rearrangement of PDGFRB might be better classified as a distinct subgroup of MPD/MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP349706.RAf3w2LwF3gvMjBdzhuqZS9tQjel9GGPsNYQ1bmuR1zMw130_provenance.
- NP349706.RAf3w2LwF3gvMjBdzhuqZS9tQjel9GGPsNYQ1bmuR1zMw130_assertion evidence source_evidence_literature NP349706.RAf3w2LwF3gvMjBdzhuqZS9tQjel9GGPsNYQ1bmuR1zMw130_provenance.
- NP349706.RAf3w2LwF3gvMjBdzhuqZS9tQjel9GGPsNYQ1bmuR1zMw130_assertion SIO_000772 11919393 NP349706.RAf3w2LwF3gvMjBdzhuqZS9tQjel9GGPsNYQ1bmuR1zMw130_provenance.
- NP349706.RAf3w2LwF3gvMjBdzhuqZS9tQjel9GGPsNYQ1bmuR1zMw130_assertion wasDerivedFrom befree-2016 NP349706.RAf3w2LwF3gvMjBdzhuqZS9tQjel9GGPsNYQ1bmuR1zMw130_provenance.
- NP349706.RAf3w2LwF3gvMjBdzhuqZS9tQjel9GGPsNYQ1bmuR1zMw130_assertion wasGeneratedBy ECO_0000203 NP349706.RAf3w2LwF3gvMjBdzhuqZS9tQjel9GGPsNYQ1bmuR1zMw130_provenance.